Product Information
ACETAZOLAMIDE ER 500 MG CAP is a generic product labeled by AvPAK, priced at $0.2882 per EA under NDC 50268004212. Its NADAC has been published 196 times since Jan 4, 2023.
FDA first approved this application on Oct 1, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
AvPAKNDC
50268004212
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAZOLAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207401FDA Approved
10/1/2020
TE Code
AB
On Market Since
7/20/2022
Pharmacological Classes
Price Statistics
The NADAC for ACETAZOLAMIDE ER 500 MG CAP has been published 196 times since Jan 4, 2023, and over the history we have for it it has declined 18.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2882 per EA |
|---|---|
| All-time high | $0.3843 (Feb 15, 2023) |
| All-time low | $0.2206 (Nov 20, 2024) |
| 52-week high | $0.3055 |
| 52-week low | $0.2653 |
| Median price | $0.3036 |
| Average price | $0.3105 |
| Largest weekly change | -23.3% (Nov 20, 2024) |
| Weeks tracked | 196 |
| Tracking since | Jan 4, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Acetazolamide Extended-Release market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AvPAK manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetazolamide Extended-Release market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Carbonic Anhydrase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ACETAZOLAMIDE ER 500 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for ACETAZOLAMIDE ER 500 MG CAP, manufactured by AvPAK, is $0.2882 per EA (NDC 50268004212), effective Sep 30, 2026.
How has the price of ACETAZOLAMIDE ER 500 MG CAP changed over time?
Over the history we have for it, the NADAC for ACETAZOLAMIDE ER 500 MG CAP has declined 18.7%. It has been tracked across 196 weekly CMS publications since Jan 4, 2023.
What are the highest and lowest recorded NADAC prices for ACETAZOLAMIDE ER 500 MG CAP?
Since Jan 4, 2023, the NADAC for ACETAZOLAMIDE ER 500 MG CAP has ranged from a low of $0.2206 (Nov 20, 2024) to a high of $0.3843 (Feb 15, 2023), with a median of $0.3036 per EA.
Are there cheaper alternatives to ACETAZOLAMIDE ER 500 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of ACETAZOLAMIDE ER 500 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ACETAZOLAMIDE ER 500 MG CAP?
ACETAZOLAMIDE ER 500 MG CAP (NDC 50268004212) is labeled by AvPAK, and CMS classifies it as a generic product.